Mainstream

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook

Post ContentymabRead More

You might also be interested in reading Tether settles Celsius claims for $300M, raising stablecoin liability concerns.

May 13, 2025
In Mainstream